Cyclacel Pharmaceuticals Files Amendment to S-1 Registration Statement
Ticker: BGMSP · Form: S-1/A · Filed: Apr 25, 2024 · CIK: 1130166
Sentiment: neutral
Topics: S-1/A, Registration Statement, Amendment, Cyclacel Pharmaceuticals, SEC Filing
TL;DR
<b>Cyclacel Pharmaceuticals filed an S-1/A amendment, updating its registration statement for potential future offerings.</b>
AI Summary
Cyclacel Pharmaceuticals, Inc. (BGMSP) filed a Amended IPO Registration (S-1/A) with the SEC on April 25, 2024. Cyclacel Pharmaceuticals, Inc. filed an amendment (S-1/A) to its registration statement on April 25, 2024. The filing is designated as Amendment No. 2 to Form S-1. The company is incorporated in Delaware and its fiscal year ends on December 31. The principal executive offices are located at 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922. Cyclacel Pharmaceuticals, Inc. was formerly known as Xcyte Therapies Inc, with a name change date of December 18, 2000.
Why It Matters
For investors and stakeholders tracking Cyclacel Pharmaceuticals, Inc., this filing contains several important signals. This amendment indicates ongoing efforts by Cyclacel Pharmaceuticals to potentially raise capital or register securities for future sale. The filing provides updated corporate information, including its former name and incorporation details, which is crucial for investors tracking the company's history and structure.
Risk Assessment
Risk Level: low — Cyclacel Pharmaceuticals, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, which is a standard procedural document and does not contain new material financial or operational information that would significantly alter the company's risk profile.
Analyst Insight
Monitor future filings for details on any securities offerings or significant corporate actions resulting from this registration statement.
Key Numbers
- 333-278197 — Registration Statement Number (SEC Registration Statement Number)
- 2024-04-25 — Filing Date (Date of filing S-1/A)
- 1231 — Fiscal Year End (Company's Fiscal Year End)
- 07922 — ZIP Code (Business Address ZIP Code)
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- S-1/A (filing) — Form Type
- 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922 (address) — Principal Executive Offices
- XCYTE THERAPIES INC (company) — Former Company Name
- 2000-12-18 (date) — Date of Name Change
- Spiro Rombotis (person) — President & Chief Executive Officer
FAQ
When did Cyclacel Pharmaceuticals, Inc. file this S-1/A?
Cyclacel Pharmaceuticals, Inc. filed this Amended IPO Registration (S-1/A) with the SEC on April 25, 2024.
What is a S-1/A filing?
A S-1/A is a amendment to an IPO registration statement, typically incorporating SEC feedback. This particular S-1/A was filed by Cyclacel Pharmaceuticals, Inc. (BGMSP).
Where can I read the original S-1/A filing from Cyclacel Pharmaceuticals, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Cyclacel Pharmaceuticals, Inc..
What are the key takeaways from Cyclacel Pharmaceuticals, Inc.'s S-1/A?
Cyclacel Pharmaceuticals, Inc. filed this S-1/A on April 25, 2024. Key takeaways: Cyclacel Pharmaceuticals, Inc. filed an amendment (S-1/A) to its registration statement on April 25, 2024.. The filing is designated as Amendment No. 2 to Form S-1.. The company is incorporated in Delaware and its fiscal year ends on December 31..
Is Cyclacel Pharmaceuticals, Inc. a risky investment based on this filing?
Based on this S-1/A, Cyclacel Pharmaceuticals, Inc. presents a relatively low-risk profile. The filing is an amendment to a registration statement, which is a standard procedural document and does not contain new material financial or operational information that would significantly alter the company's risk profile.
What should investors do after reading Cyclacel Pharmaceuticals, Inc.'s S-1/A?
Monitor future filings for details on any securities offerings or significant corporate actions resulting from this registration statement. The overall sentiment from this filing is neutral.
How does Cyclacel Pharmaceuticals, Inc. compare to its industry peers?
Cyclacel Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of novel therapies.
Are there regulatory concerns for Cyclacel Pharmaceuticals, Inc.?
The filing is made under the Securities Act of 1933, which governs the registration of securities.
Industry Context
Cyclacel Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on the development of novel therapies.
Regulatory Implications
The filing is made under the Securities Act of 1933, which governs the registration of securities.
What Investors Should Do
- Review the full S-1/A filing for any specific details regarding proposed securities offerings.
- Track future SEC filings from Cyclacel Pharmaceuticals for updates on their business and financial activities.
- Research the company's historical performance and pipeline if considering investment based on this filing.
Key Dates
- 2024-04-25: Filing of S-1/A Amendment — Updates the registration statement for potential securities offerings.
- 2000-12-18: Name Change — Indicates the company's former name was XCYTE THERAPIES INC.
Year-Over-Year Comparison
This is an amendment to a previously filed registration statement, indicating ongoing regulatory processes rather than a new filing.
Filing Stats: 4,521 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2024-04-24 18:50:55
Key Financial Figures
- $1.68 — sumed combined public offering price of $1.68 per share of common stock and accompany
- $0.0001 — common stock in this offering less the $0.0001 per share exercise price of each such p
- $1.6799 — ffering price per pre-funded warrant of $1.6799 and accompanying Common Stock Warrants.
- $2,500,000 — Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for conti
- $607,000 — o;). Our stockholders’ equity was $607,000 as of December 31, 2023 and, as a resul
- $3.4 million — e that our cash and cash equivalents of $3.4 million as of December 31, 2023 will allow us t
- $2.7 million — cash balance on hand was approximately $2.7 million. There is no guarantee that we will be
- $0 — d to the public in this offering, minus $0.0001, and the exercise price of each pr
Filing Documents
- tm249520d5_s1.htm (S-1/A) — 585KB
- tm249520d5_ex-filingfees.htm (EX-FILING FEES) — 49KB
- tm249520d5_s1img001.jpg (GRAPHIC) — 2KB
- 0001104659-24-051334.txt ( ) — 638KB
RISK FACTORS
RISK FACTORS 5 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 7
USE OF PROCEEDS
USE OF PROCEEDS 8 MARKET FOR OUR COMMON STOCK 8 DIVIDEND POLICY 8 CAPITALIZATION 9
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 12 MANAGEMENT AND CORPORATE GOVERNANCE 13 EXECUTIVE AND DIRECTOR COMPENSATION 18 EQUITY COMPENSATION PLAN INFORMATION 21 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 26 DESCRIPTION OF OUR COMMON STOCK 27 DESCRIPTION OF OUR PREFERRED STOCK 28 DESCRIPTION OF OUTSTANDING WARRANTS 36 DESCRIPTION OF THE SECURITIES WE ARE OFFERING 39 PLAN OF DISTRIBUTION 43 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 45 LEGAL MATTERS 45 EXPERTS 45 WHERE YOU CAN FIND MORE INFORMATION 45 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 46 i You should read this prospectus and any applicable prospectus supplement before making an investment in the securities of Cyclacel Pharmaceuticals, Inc. See “Where You Can Find More Information” for more information. You should rely only on the information contained in this prospectus or a prospectus supplement. The Company has not authorized anyone to provide you with different information. This document may be used only in jurisdictions where offers and sales of these securities are permitted. You should assume that information contained in this prospectus, or in any prospectus supplement, is accurate only as of any date on the front cover of the applicable document. Our business, financial condition, results of operations and prospects may have changed since that date. Unless otherwise noted in this prospectus, “Cyclacel Pharmaceuticals,” “Cyclacel,” “the Company,” “we,” “us,” “our” and similar terms refer to Cyclacel Pharmaceuticals, Inc. Smaller Reporting Company - Scaled Disclosure Pursuant to Item 10(f) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Securities Act”), as indicated herein, we have elected to comply with the scaled disclosure requirements applicabl